Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Top Cited Papers
- 10 June 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (34), 2288-2296
- https://doi.org/10.1093/eurheartj/ehv239
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular risk factors (CVRFs) and reduce cardiovascular morbidity and mortality. In this review, we examine the effect of oral (metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP4 inhibitors, SGLT2 inhibitors, and α-glucosidase inhibitors) and injectable (glucagon-like peptide-1 receptor agonists and insulin) glucose-lowering drugs on established CVRFs and long-term studies of cardiovascular outcomes. Firm evidence that in T2DM cardiovascular disease can be reversed or prevented by improving glycaemic control is still incomplete and must await large, long-term clinical trials in patients at low risk using modern treatment strategies, i.e. drug combinations designed to maximize HbA1c reduction while minimizing hypoglycaemia and excessive weight gain.Keywords
This publication has 105 references indexed in Scilit:
- Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III TrialCardiovascular Drugs and Therapy, 2012
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trialsDiabetes & Metabolism, 2012
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009Diabetologia, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of Internal Medicine, 2008
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Coronary Artery Calcification Compared With Carotid Intima-Media Thickness in the Prediction of Cardiovascular Disease IncidenceThe Multi-Ethnic Study of Atherosclerosis (MESA)JAMA Internal Medicine, 2008
- Metabolic syndrome: Evaluation of pathological and therapeutic outcomesAmerican Heart Journal, 2005
- The effect of insulin on the incorporation of sodium (1-14C)-acetate into the lipids of the rat aortaDiabetologia, 1971